AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deSEP 252 min read$INBP

Integrated BioPharma, Inc.: Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026

Integrated BioPharma, Inc. (INBP) reported a 31% revenue decline to $9.8M for Q2 2026 and a 19% drop to $43.9M for the fiscal year, with net losses of $1.4M and $2.8M, respectively. The company attributed the decrease to reduced revenue from its two largest customers, according to its executives.

Original reporting
finanznachrichten.de
Published Sep 25, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$INBP
Bearish
medium confidence
Mentioned
$INBP
Relevance
6/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$INBPBearishMed
01

Why it matters

The earnings miss underscores challenges in its two largest customers, which together accounted for ~90% of revenue, raising concerns about customer concentration.

02

Market read

The earnings decline may trigger short‑term selling pressure on INBP, while the broader market remains largely unaffected.

03

What to watch

Potential cost‑cutting measures or upcoming product launches not disclosed in the release.

Relevance 6/10Novelty 6/10Timing: post‑market release September 25, 2026

Background

Integrated BioPharma, an OTCQX listed contract manufacturer of vitamins and supplements, issued its FY 2026 earnings release.

Company-level read

Ticker impact

$INBPBearishMedium confidence
Context

Integrated BioPharma reported Q2 and FY 2026 results showing 31% revenue decline and a net loss of $2.8M, a material deterioration from the prior year.

Expected impact

downward pressure in the near term

Evidence & confidence

The company posted a sizable revenue decline and swung to a net loss, indicating weaker demand and higher risk.

Market effects

Sector

Highlights weakness in the nutraceutical contract‑manufacturing segment.

Regional

Limited to U.S. OTC market; no broader regional effect.

Global

Minimal, as the company is a micro‑cap with niche exposure.

Counterpoint

What could challenge this read

If the revenue decline is temporary and the company secures new contracts, the stock could rebound.

Key entities

  • Company
    Integrated BioPharma, Inc.

    OTCQX listed manufacturer of nutraceutical products.

  • Executive
    Riva Sheppard

    Co‑Chief Executive Officer of Integrated BioPharma.

  • Executive
    Christina Kay

    Co‑Chief Executive Officer of Integrated BioPharma.

Read at source← All news

Related articles

SEP 25
$INBPMed

INTEGRATED BIOPHARMA INC (INBP): Results of Operations and Financial Condition

INTEGRATED BIOPHARMA INC (INBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE for September 25, 2026 Contact: Dina Masi, CFO Integrated BioPharma, Inc. investors@ibiopharma.com 888.319.6962 Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026 HILLSIDE, NEW JERSEY (September 25, 2026) - Integrate

SEC EDGAR 8-K2 min
SEP 27
$PAYXHighAI 9/10

Paychex Reports $1.63 Billion In Q1 Revenue As Net Income Increases 12% To $429.7 Million

Paychex reported Q1 2027 revenue of $1.63B, up 6% YoY, with net income rising 12% to $429.7M. Growth was driven by payroll, human capital management, and PEO businesses. Operating income increased 14% to $619.2M, while operating margin improved to 38%. The company also reported higher interest income and reduced acquisition-related expenses. Paychex declared $423.6M in dividends and has a $1B share repurchase program.

pulse2.com2 min
SEP 27
$005930.KSHighAI 8/10

Samsung forecast to post record quarterly operating profit

Samsung Electronics is projected to report a record quarterly operating profit of 107.7 trillion won, a 20.3% increase from the previous quarter, according to analysts. The company's semiconductor division is expected to achieve a 72–75% operating margin, with DRAM margins potentially exceeding 80%. TrendForce forecasts a 13–18% rise in DRAM prices for the third quarter.

ua.news2 min
SEP 27
$005930.KSMedAI 8/10

Samsung eyes record W100tr profit as DRAM margin seen at 80%

Samsung Electronics is expected to report a record quarterly operating profit of 107.7 trillion won, up 20.3% from the previous quarter, driven by strong DRAM margins. Analysts attribute this to a shift in production capacity towards high-bandwidth memory and server products, tightening supply and extending delivery times. DRAM prices are forecast to rise 13-18% on-quarter, though this is a slowdown from the prior quarter's 60% increase.

koreaherald.com2 min
SEP 27
$CTASMedAI 8/10

How Raised Guidance At Cintas Stock Has Changed Its Investment Story

Cintas (CTAS) reported Q1 2027 sales of $2.29B, revenue of $3.01B, and net income of $551.71M. The company raised full-year revenue guidance to $12.15B-$12.27B, reflecting management's confidence in demand and cost structure. The investment narrative focuses on recurring workplace services and cross-selling potential, with risks tied to remote work trends and automation. Analysts expect 7.3% yearly revenue growth through 2029.

simplywall.st3 min